In this article (Clin Cancer Res 2014;20:5908–17), which was published in the December 1, 2014, issue of Clinical Cancer Research (1), one of the authors' names was misprinted. The corrected name should read as follows: “Aurelius Omlin.” The publisher regrets this error.

1.
Blagden
S
,
Omlin
A
,
Josephs
D
,
Stavraka
C
,
Zivi
A
,
Pinato
DJ
, et al
First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer
.
Clin Cancer Res
2014
;
20
:
5908
17
.